Insulet Corporation (PODD)
| Market Cap | 10.58B -55.4% |
| Revenue (ttm) | 3.19B +26.5% |
| Net Income | 428.70M +74.1% |
| EPS | 6.13 +77.6% |
| Shares Out | 69.37M |
| PE Ratio | 24.88 |
| Forward PE | 20.30 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,590,978 |
| Open | 150.47 |
| Previous Close | 149.29 |
| Day's Range | 145.31 - 153.79 |
| 52-Week Range | 126.40 - 354.88 |
| Beta | 1.05 |
| Analysts | Buy |
| Price Target | 178.57 (+17.11%) |
| Earnings Date | Nov 4, 2026 |
About PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controll... [Read more]
Financial Performance
In 2025, Insulet's revenue was $2.71 billion, an increase of 30.73% compared to the previous year's $2.07 billion. Earnings were $247.10 million, a decrease of -40.93%.
Financial StatementsAnalyst Summary
According to 26 analysts, the average rating for PODD stock is "Buy." The 12-month stock price target is $178.57, which is an increase of 17.11% from the latest price.
News
Insulet price target raised to $160 from $153 at Truist
Truist raised the firm’s price target on Insulet (PODD) to $160 from $153 and keeps a Hold rating on the shares after its Q3 earnings beat. The company also guided…
Insulet launches ‘Give Yourself the Freedom to’ campaign
In recognition of World Diabetes Day on November 14, Insulet (PODD) Corporation announced its “Give Yourself the Freedom to” campaign designed to raise awareness of the often overlooked emotional and…
For World Diabetes Day, Insulet Launches “Give Yourself the Freedom to” Campaign, Encouraging People with Diabetes to Prioritize Their Well-Being
ACTON, Mass.--(BUSINESS WIRE)--In recognition of World Diabetes Day on November 14, 2026, Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump techno...
Insulet price target raised to $165 from $150 at Barclays
Barclays raised the firm’s price target on Insulet (PODD) to $165 from $150 and keeps an Equal Weight rating on the shares.
Insulet price target raised to $180 from $160 at RBC Capital
RBC Capital analyst Kendall Au raised the firm’s price target on Insulet (PODD) to $180 from $160 and keeps an Outperform rating on the shares. The company lowered its FY27…
Insulet price target raised to $170 from $152 at JPMorgan
JPMorgan raised the firm’s price target on Insulet (PODD) to $170 from $152 and keeps a Neutral rating on the shares.
Insulet price target raised to $171 from $150 at UBS
UBS raised the firm’s price target on Insulet (PODD) to $171 from $150 and keeps a Neutral rating on the shares.
Insulet price target raised to $200 from $175 at Baird
Baird raised the firm’s price target on Insulet (PODD) to $200 from $175 and keeps an Outperform rating on the shares.
Insulet price target raised to $170 from $150 at Citi
Citi raised the firm’s price target on Insulet (PODD) to $170 from $150 and keeps a Neutral rating on the shares.
Insulet price target raised to $200 from $175 at Bernstein
Bernstein raised the firm’s price target on Insulet (PODD) to $200 from $175 and keeps an Outperform rating on the shares. The firm notes the company reported a huge Q3…
Insulet price target raised to $200 from $175 at Baird
Baird raised the firm’s price target on Insulet (PODD) to $200 from $175 and keeps an Outperform rating on the shares.
Insulet price target raised to $180 from $160 at RBC Capital
RBC Capital raised the firm’s price target on Insulet (PODD) to $180 from $160 and keeps an Outperform rating on the shares.
Insulet Earnings Call Transcript: Q3 2026
Q3 revenue rose 19.2% reported, with adjusted margins and EPS expanding sharply; FY26 growth guidance moved to the top end of the prior range. Growth is expected to moderate in 2027 as competition rises and international comparisons toughen.
Insulet Earnings release: Q3 2026
Insulet released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Insulet Slides: Q3 2026
Insulet has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
Insulet Quarterly report: Q3 2026
Insulet has published its Q3 2026 quarterly earnings report on November 4, 2026.
Insulet reports Q3 adjusted EPS $1.99, consensus $1.59
Reports Q3 revenue $842M, consensus $832.64M. “Our team delivered a strong quarter, with revenue growth of nearly 20% and significant margin expansion,” said Ashley McEvoy, President and CEO. “We are…
Insulet Reports Third Quarter 2026 Results
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
Insulet Slides: Investor presentation
Insulet has posted slides in relation to its latest quarterly earnings report, which was published on November 4, 2026.
Insulet to Participate in the 2026 Jefferies Global Healthcare Conference in London
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will prese...
Insulet price target lowered to $190 from $275 at Jefferies
Jefferies analyst Matthew Taylor lowered the firm’s price target on Insulet (PODD) to $190 from $275 and keeps a Buy rating on the shares. The firm’s lowered target accounts for…
Insulet announces U.S. full market release of Omnipod Discover
Insulet (PODD) announced the U.S. full market release of Omnipod Discover. “The future of diabetes care is not just about generating more data, it’s about making that data meaningful,” said…
Insulet Announces Omnipod Discover Now Available in U.S.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the U.S. full market relea...